NCT00184561已完成4 期
Change in HbA1c With Biphasic Insulin Aspart 70/30 in Two Different Treatment Regiments in Subjects With Type 2 Diabetes Inadequately Controlled With Oral Anti-diabetic Drug Therapy.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 321
- 试验地点
- 8
- 主要终点
- Change in HbA1c
研究概览
简要总结
This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type 2 diabetes, not well controlled on their current oral anti-diabetic drug therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes
- •HbA1C = 7.5%
- •Insulin naïve
- •Current treatment by Oral Anti-diabetic Drugs
排除标准
- •Severe medical conditions
结局指标
主要结局
Change in HbA1c
时间窗: After 24 weeks of treatment
次要结局
- Hypoglycaemic episodes
- Weight change
- 2-hour postprandial blood glucose
- after 24 weeks of treatment.
- Fasting blood glucose
- Adverse events
研究者
研究点 (8)
Loading locations...
相似试验
已完成
4 期
Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal InsulinDiabetesDiabetes Mellitus, Type 2NCT00669864Novo Nordisk A/S293
已完成
3 期
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00627445Novo Nordisk A/S441
已完成
4 期
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756DiabetesDiabetes Mellitus, Type 2NCT01278160Novo Nordisk A/S179
已完成
4 期
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00600366Novo Nordisk A/S71
已完成
3 期
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD TherapyDiabetes Mellitus, Type 2DiabetesNCT00598793Novo Nordisk A/S242